Page 2 - Sciences Group News Today

SELLAS Life Sciences Group, Inc. announced topline data from the Phase 2a study of SLS009 and provides an update on Phase 3 REGAL Study of GPS in AML. The REGAL Steering Committee met on March 22,...

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April-

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase...

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 3,120,000 shares, a decrease of 19.6% from the January 15th total of 3,880,000 shares. Based on an average daily trading volume, of 990,800 shares, […]

Rick Guiney, chief executive of MicroSalt, commented: We are delighted to announce our successful fundraise and admission to AIM.

Key Insights Significantly high institutional ownership implies Location Sciences Group's stock price is sensitive to...

Location Sciences Group PLC on Tuesday announced plans to change its name, its CEO and its CFO after agreeing a reverse takeover of Sorted Holdings Ltd. Late on Tuesday morning in London, the stock...

SHANGHAI - GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug Administration has recently...

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S....